“Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study”. (2023) Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023061. doi:10.4084/MJHID.2023.061.